JP2002517486A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002517486A5 JP2002517486A5 JP2000553409A JP2000553409A JP2002517486A5 JP 2002517486 A5 JP2002517486 A5 JP 2002517486A5 JP 2000553409 A JP2000553409 A JP 2000553409A JP 2000553409 A JP2000553409 A JP 2000553409A JP 2002517486 A5 JP2002517486 A5 JP 2002517486A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutical composition
- compound
- treating
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 26
- 239000008194 pharmaceutical composition Substances 0.000 description 25
- -1 methoxy, cyano, nitro, amino, hydroxy, methyl Chemical group 0.000 description 24
- 239000003814 drug Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000004770 neurodegeneration Effects 0.000 description 6
- 208000015122 neurodegenerative disease Diseases 0.000 description 6
- 208000020084 Bone disease Diseases 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 230000001066 destructive effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 230000007954 hypoxia Effects 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010058019 Cancer Pain Diseases 0.000 description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 2
- 208000006029 Cardiomegaly Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010033647 Pancreatitis acute Diseases 0.000 description 2
- 206010033649 Pancreatitis chronic Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010063897 Renal ischaemia Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 206010043781 Thyroiditis chronic Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 231100000354 acute hepatitis Toxicity 0.000 description 2
- 201000003229 acute pancreatitis Diseases 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 201000005000 autoimmune gastritis Diseases 0.000 description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
- 125000003627 8 membered carbocyclic group Chemical group 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 208000001969 capillary hemangioma Diseases 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8914798P | 1998-06-12 | 1998-06-12 | |
| US60/089,147 | 1998-06-12 | ||
| PCT/US1999/012951 WO1999064400A1 (en) | 1998-06-12 | 1999-06-11 | INHIBITORS OF p38 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002517486A JP2002517486A (ja) | 2002-06-18 |
| JP2002517486A5 true JP2002517486A5 (https=) | 2006-07-20 |
Family
ID=22215952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000553409A Pending JP2002517486A (ja) | 1998-06-12 | 1999-06-11 | ｐ３８のインヒビター |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US6528508B2 (https=) |
| EP (1) | EP1086085A1 (https=) |
| JP (1) | JP2002517486A (https=) |
| AU (1) | AU4429799A (https=) |
| WO (1) | WO1999064400A1 (https=) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2294057A1 (en) | 1997-06-13 | 1998-12-17 | Smithkline Beecham Corporation | Novel pyrazole and pyrazoline substituted compounds |
| US6858617B2 (en) | 1998-05-26 | 2005-02-22 | Smithkline Beecham Corporation | Substituted imidazole compounds |
| JP2003525201A (ja) | 1998-08-20 | 2003-08-26 | スミスクライン・ビーチャム・コーポレイション | 新規な置換トリアゾール化合物 |
| WO2000025791A1 (en) | 1998-11-04 | 2000-05-11 | Smithkline Beecham Corporation | Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines |
| WO2000075118A1 (en) * | 1999-06-03 | 2000-12-14 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) |
| MXPA02004330A (es) * | 1999-11-03 | 2004-07-30 | Albany Molecular Res Inc | Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina.. |
| EP1248624A4 (en) * | 1999-11-23 | 2003-01-22 | Smithkline Beecham Corp | 3,4-DIHYDRO- (1H) -CHIRAZOLINE-2-ONES AND THE USE THEREOF AS CSBP / P38 KINASE INHIBITORS |
| AU1781601A (en) | 1999-11-23 | 2001-06-04 | Smithkline Beecham Corporation | 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
| ATE305787T1 (de) * | 1999-11-23 | 2005-10-15 | Smithkline Beecham Corp | 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren |
| EP1233951B1 (en) * | 1999-11-23 | 2005-06-01 | SmithKline Beecham Corporation | 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
| US6759410B1 (en) * | 1999-11-23 | 2004-07-06 | Smithline Beecham Corporation | 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors |
| MY141144A (en) * | 2000-03-02 | 2010-03-15 | Smithkline Beecham Corp | 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| US7235551B2 (en) * | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| JP2004511542A (ja) * | 2000-10-19 | 2004-04-15 | スミスクライン・ビーチャム・コーポレイション | 煙の吸入の治療のためのｐ３８阻害剤の使用 |
| ATE521353T1 (de) * | 2000-10-23 | 2011-09-15 | Glaxosmithkline Llc | Neues trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-onderivat zur behandlung von durch csbp/p38kinase vermittelten krankheiten |
| EP1345603A4 (en) * | 2000-12-20 | 2004-09-08 | Merck & Co Inc | (HALO-BENZO-CARBONYL) HETEROCYCLO-CONDENSED PHENYL-P38-KINASE INHIBITING AGENTS |
| PA8539401A1 (es) * | 2001-02-14 | 2002-10-28 | Warner Lambert Co | Quinazolinas como inhibidores de mmp-13 |
| ATE415162T1 (de) | 2001-06-11 | 2008-12-15 | Vertex Pharma | Isochinolin-inhibitoren von p38 |
| GB0124848D0 (en) * | 2001-10-16 | 2001-12-05 | Celltech R&D Ltd | Chemical compounds |
| MXPA04010186A (es) * | 2002-04-18 | 2005-02-03 | Pharmacia Corp | Monoterapia para el tratamiento de la enfermedad de parkinson con inhibidor (es) de la ciclooxigenasa-2 (cox 2). |
| EP1494664A2 (en) * | 2002-04-18 | 2005-01-12 | Pharmacia Corporation | Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease |
| KR20040103972A (ko) | 2002-04-19 | 2004-12-09 | 스미스클라인 비참 코포레이션 | 신규 화합물 |
| EP1515727A4 (en) * | 2002-06-11 | 2009-04-08 | Merck & Co Inc | (HALO-BENZO CARBONYL) HETEROBICYCLIC P38 KINASE INHIBITION |
| GB0214268D0 (en) * | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
| DE60310730T2 (de) | 2002-07-09 | 2007-05-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege |
| WO2004014378A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
| GB0218800D0 (en) * | 2002-08-13 | 2002-09-18 | Celltech R&D Ltd | Chemical compounds |
| AU2003250475A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
| EP1539121A4 (en) | 2002-08-29 | 2008-08-13 | Scios Inc | METHOD OF REQUESTING OSTEOGENESIS |
| JP2006503025A (ja) * | 2002-09-05 | 2006-01-26 | サイオス インク． | ｐ３８ＭＡＰキナーゼの抑制による疼痛治療 |
| US20080039461A1 (en) * | 2002-09-05 | 2008-02-14 | Protter Andrew A | Treatment of pain by inhibition of p38 map kinase |
| GB0222743D0 (en) * | 2002-10-01 | 2002-11-06 | Celltech R&D Ltd | Chemical compounds |
| JP5204947B2 (ja) | 2002-11-27 | 2013-06-05 | ディーエムアイ バイオサイエンシズ インコーポレイテッド | リン酸受容体化合物の使用、ならびにリン酸受容体化合物を含んでいる、薬学的組成物、スキンケア用の組成物、およびキット |
| US7183287B2 (en) * | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
| US20070167621A1 (en) | 2003-04-03 | 2007-07-19 | Pharmacia Corporation | Substituted pyrimidinones |
| WO2004101529A1 (ja) * | 2003-05-19 | 2004-11-25 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびその医薬用途 |
| EP1641804A1 (en) | 2003-06-20 | 2006-04-05 | Celltech R & D Limited | Thienopyridone derivatives as kinase inhibitors |
| JP2005045206A (ja) * | 2003-07-07 | 2005-02-17 | Dainippon Screen Mfg Co Ltd | 基板処理方法および基板処理装置 |
| US7244441B2 (en) | 2003-09-25 | 2007-07-17 | Scios, Inc. | Stents and intra-luminal prostheses containing map kinase inhibitors |
| AU2004285752A1 (en) * | 2003-10-24 | 2005-05-12 | Ucb Pharma S.A. | Thieno-pyridinone derivatives as kinase inhibitors |
| AU2004297235A1 (en) | 2003-12-04 | 2005-06-23 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| EP2708531A1 (en) * | 2004-10-13 | 2014-03-19 | Pharmacia & Upjohn Company LLC | Crystalline Forms Of 3-[5-Chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| EP1676574A3 (en) | 2004-12-30 | 2006-07-26 | Johnson & Johnson Vision Care, Inc. | Methods for promoting survival of transplanted tissues and cells |
| EP1865959A2 (en) | 2005-03-25 | 2007-12-19 | Glaxo Group Limited | Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives |
| WO2006110298A2 (en) * | 2005-03-25 | 2006-10-19 | Glaxo Group Limited | 8-alkyl/aryl-4-aryl-2-n- (alkylamino)-n'-substituted-n'-cyanoguanidino-8h-pyrido[2,3-d]pyrimidin-7-one compounds and use thereof |
| UY29440A1 (es) * | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | Nuevos compuestos |
| UY29439A1 (es) | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | Nuevos compuestos |
| WO2006118914A2 (en) * | 2005-04-29 | 2006-11-09 | Children's Medical Center Corporation | Methods of increasing proliferation of adult mammalian cardiomyocytes through p38 map kinase inhibition |
| JP2010513370A (ja) * | 2006-12-19 | 2010-04-30 | エフ．ホフマン−ラ ロシュ アーゲー | ピラゾロ［３，４−ｄ］ピリミジンｐ３８ＭＡＰキナーゼインヒビター |
| ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
| CA2681420A1 (en) * | 2007-03-20 | 2008-09-25 | Cadila Pharmaceuticals Limited | P38 inhibitors |
| ES2329639B1 (es) | 2007-04-26 | 2010-09-23 | Laboratorios Almirall S.A. | Nuevos derivados de 4,8-difenilpoliazanaftaleno. |
| EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
| EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
| EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
| WO2010038428A1 (ja) * | 2008-09-30 | 2010-04-08 | 武田薬品工業株式会社 | タキサン系抗がん剤の置き換え薬 |
| US20110230465A1 (en) * | 2009-09-18 | 2011-09-22 | Boehringer Ingleheim International Gmbh | Viral polymerase inhibitors |
| AU2010301449B2 (en) | 2009-09-30 | 2013-03-14 | Toray Industries, Inc. | 2,3-dihydro-1H-indene-2-ylurea derivative and pharmaceutical application of same |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| ES2704744T3 (es) | 2012-06-13 | 2019-03-19 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MX373169B (es) | 2015-02-20 | 2020-04-24 | Incyte Holdings Corp | Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr). |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2017075274A1 (en) | 2015-10-27 | 2017-05-04 | Children's Hospital Medical Center | Use of mapk inhibitors to reduce loss of hematopoietic stem cells during ex vivo culture and/or genetic manipulation |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| WO2019071147A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| EP3773579A4 (en) | 2018-03-26 | 2022-03-09 | Clear Creek Bio, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE |
| UA127059C2 (uk) | 2018-03-30 | 2023-03-29 | Ле Лаборатуар Сервьє | Гетеробіциклічні інгібітори mat2a і способи використання для лікування злоякісної пухлини |
| CR20200590A (es) | 2018-05-04 | 2021-04-26 | Incyte Corp | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas |
| MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TWI891666B (zh) | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US20210300873A1 (en) | 2020-03-20 | 2021-09-30 | Clear Creek Bio, Inc. | Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| SMT202500271T1 (it) | 2020-07-02 | 2025-09-12 | Incyte Corp | Composti di urea triciclici come inibitori di v617f di jak2 |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN114262294B (zh) * | 2022-01-06 | 2023-09-22 | 成都中医药大学 | 一种苯基异喹啉生物碱化合物及其制备方法与应用 |
| CN119173514A (zh) | 2022-03-17 | 2024-12-20 | 因赛特公司 | 作为jak2 v617f抑制剂的三环脲化合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE272843C (https=) * | ||||
| GB8509834D0 (en) * | 1985-04-17 | 1985-05-22 | Beecham Group Plc | Compounds |
| HUP9900169A2 (hu) * | 1995-09-13 | 2000-03-28 | Takeda Chemical Industries, Ltd. | Immunoszuppresszáns hatású kinolin- vagy kinozalinszármazékok és ezeket tartalmazó gyógyászati készítmények |
| US6096748A (en) * | 1996-03-13 | 2000-08-01 | Smithkline Beecham Corporation | Pyrimidine compounds useful in treating cytokine mediated diseases |
| US6235760B1 (en) * | 1996-03-25 | 2001-05-22 | Smithkline Beecham Corporation | Treatment for CNS injuries |
| WO1998007425A1 (en) * | 1996-08-21 | 1998-02-26 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
| US6147080A (en) * | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
-
1999
- 1999-06-11 JP JP2000553409A patent/JP2002517486A/ja active Pending
- 1999-06-11 WO PCT/US1999/012951 patent/WO1999064400A1/en not_active Ceased
- 1999-06-11 EP EP99927377A patent/EP1086085A1/en not_active Withdrawn
- 1999-06-11 AU AU44297/99A patent/AU4429799A/en not_active Abandoned
-
2000
- 2000-12-11 US US09/734,069 patent/US6528508B2/en not_active Expired - Lifetime
-
2002
- 2002-12-20 US US10/327,020 patent/US6800626B2/en not_active Expired - Fee Related
-
2004
- 2004-09-27 US US10/951,409 patent/US7151101B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002517486A5 (https=) | ||
| JP2002526482A5 (https=) | ||
| JP2002514625A5 (https=) | ||
| JP2003528084A5 (https=) | ||
| CA2331460A1 (en) | Heterocyclic inhibitors of p38 | |
| JP2002526501A5 (https=) | ||
| RU2012105914A (ru) | Эффективные низкомолекулярные ингибиторы аутофагии и способ их применения | |
| RU2002127682A (ru) | Замещенные бета-карболины | |
| CA2496676A1 (en) | 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands | |
| CA2339761A1 (en) | Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) | |
| JP2018507238A5 (https=) | ||
| JP2005505618A5 (https=) | ||
| JP2003531103A5 (https=) | ||
| JP2006512339A5 (https=) | ||
| JP2010500293A5 (https=) | ||
| JP2004514663A5 (https=) | ||
| JP2010536887A5 (https=) | ||
| JP2002503220A (ja) | 超短時間作用性神経筋遮断薬としての置換イソキノリン類 | |
| JP2019500315A5 (https=) | ||
| EP0092391A3 (en) | Novel piperidine derivatives and pharmaceutical compositions containing same | |
| AU2001283237B2 (en) | Pyridine derivatives as inhibitors of p38 | |
| JP2007523177A5 (https=) | ||
| JP2009275054A (ja) | Ｐ３８のイソキノリンインヒビター | |
| JP2002536438A5 (https=) | ||
| CN109134481A (zh) | 一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用 |